Salivary gland cancer research addresses a rare, histologically diverse group of malignancies with few approved systemic options, including emerging biomarker-driven and HER2-directed strategies.
A single-center, non-randomized phase 2 basket trial tested ado-trastuzumab emtansine (T-DM1) across five disease-specific cohorts of HER2-amplified solid tumors, asking whether a shared molecular driver predicts benefit from a HER2-targeted antibody-drug conjugate regardless of tumor origin.
Related topics: Antibody-Drug Conjugates
Please enable JavaScript to access the latest cancer research articles and studies.